UH15-38 TFA
Based on 2 publication(s) in Google Scholar
UH15-38 TFA is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 TFA blocks IAV (influenza A virus)-activated necroptosis. UH15-38 TFA dampens IAV-induced lung injury.
For research use only. We do not sell to patients.
- Purity : 99.77%
- Formula: C28H28F3N5O4
- Molecular Weight:555.55
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) UH15-38 TFA
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
WB
-
IF
Biological Activity
Description
IC50 & Target
[1]|
RIPK3 20 nM (IC50) |
In Vitro
UH15-38 (0-1000 nM; 12 h) TFA decreases the expression of pMLKL induced by TCZ in a dose-dependent manner[1].
UH15-38 (0-1000 nM) TFA protects type I alveolar epithelial cells from canonical TNF-induced necroptosis and prevents IAV-induced necroptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse embryonic fibroblasts
-
Concentration:0, 25, 50, 100, 250, 500, 750, 1000 nM
-
Incubation Time:12 h
-
Result:Decreased the expression of pMLKL induced by TCZ (mouse TNF (100 ng/ml), cycloheximide (250 ng/ml) and zVAD (50 μM)) in a time dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6 mice (lethal dose of PR8 (6,000 × EID50))[1]
-
Dosage:30 mg/kg
-
Administration:I.p.; once daily for 4 days; starting 24 h after infection
-
Result:Markedly reduced numbers of pMLKL+ necroptotic cells, decreased in diffuse alveolar damage and the formation of hyaline membranes, reduced the extent of fibrotic lung damage, displayed significantly lower levels of the pro-fibrotic mediators (IL-1β, IL-6, IL-18, IL-17 and CCL5).
Chemical Information
-
Appearance Solid
-
Molecular Weight 555.55
-
Formula C28H28F3N5O4
-
Color Off-white to light yellow
-
SMILES
CN1CCN(CC1)C2=CC(NC3=NC=C4C=C(C(N(C4=C3)C)=O)C5=CC(O)=CC=C5)=CC=C2.O=C(C(F)(F)F)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Transbound Emerg Dis
Activation of ZBP1/RIPK3/MLKL-Dependent Necroptosis by Pseudorabies Virus Restricts Viral Infection in BV2 Microglia Cells. [Abstract]2025 Oct 7:2025:8510846. PMID: 41098523
UH15-38 TFA purchased from MedChemExpress. Usage Cited in: Transbound Emerg Dis. 2025 Oct 7:2025:8510846. [Abstract]
Cell viability of PRV-infected BV2 microglial cells treated with UH15-38 (0.01, 0.1, 1 μM).
UH15-38 TFA purchased from MedChemExpress. Usage Cited in: Transbound Emerg Dis. 2025 Oct 7:2025:8510846. [Abstract]
BV2 microglial cells were pretreated with UH15-38 (0.01, 0.1, 0.5 μM) for 1 h and then infected with PRV for 24 h. The IFN-β, ISG15, and Mx2 mRNA levels were measured by qRT-PCR.
UH15-38 TFA purchased from MedChemExpress. Usage Cited in: Transbound Emerg Dis. 2025 Oct 7:2025:8510846. [Abstract]
BV2 microglial cells were pretreated with UH15-38 (0.01, 0.1, and 0.5 μM) for 1 h, and then PRV JS-2012 was used to infect BV2 microglial cells for 24 h. Then, PRV gE expression levels were analyzed by western blot.
UH15-38 TFA purchased from MedChemExpress. Usage Cited in: Transbound Emerg Dis. 2025 Oct 7:2025:8510846. [Abstract]
BV2 microglial cells were pretreated with UH15-38 (0.01, 0.1, and 0.5 μM) for 1 h, and then PRV JS-2012 was used to infect BV2 microglial cells for 24 h. The expression of PRV gE and p-RIPK3 was visualized by IFA.
-
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (90.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.25 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.25 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8000 mL | 9.0001 mL | 18.0002 mL | 45.0005 mL |
| 5 mM | 0.3600 mL | 1.8000 mL | 3.6000 mL | 9.0001 mL | |
| 10 mM | 0.1800 mL | 0.9000 mL | 1.8000 mL | 4.5000 mL | |
| 15 mM | 0.1200 mL | 0.6000 mL | 1.2000 mL | 3.0000 mL | |
| 20 mM | 0.0900 mL | 0.4500 mL | 0.9000 mL | 2.2500 mL | |
| 25 mM | 0.0720 mL | 0.3600 mL | 0.7200 mL | 1.8000 mL | |
| 30 mM | 0.0600 mL | 0.3000 mL | 0.6000 mL | 1.5000 mL | |
| 40 mM | 0.0450 mL | 0.2250 mL | 0.4500 mL | 1.1250 mL | |
| 50 mM | 0.0360 mL | 0.1800 mL | 0.3600 mL | 0.9000 mL | |
| 60 mM | 0.0300 mL | 0.1500 mL | 0.3000 mL | 0.7500 mL | |
| 80 mM | 0.0225 mL | 0.1125 mL | 0.2250 mL | 0.5625 mL |
UH15-38 TFA Related Classifications
HY-158312A Related Classifications
Powered by Bioz